Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of CD19/BCMA-Targeted Universal Allogeneic CAR-T Cell Therapy in Relapsed/Refractory Autoimmune Hemolytic Anima: Evaluating Safety and Preliminary Efficacy

NCT07530380 is registered in ClinicalTrials.gov with The Second Hospital of Anhui Medical University as lead sponsor.

NCT NCT07530380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07530380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of CD19/BCMA-Targeted Universal Allogeneic CAR-T Cell Therapy in Relapsed/Refractory Autoimmune Hemolytic Anima: Evaluating Safety and Preliminary Efficacy
Lead sponsor
The Second Hospital of Anhui Medical University
Phase
Phase 1
Overall status
Recruiting
Start date
April 30, 2026
Completion date
December 31, 2030
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aiha - warm autoimmune hemolytic anemia, ucart